223 related articles for article (PubMed ID: 37650357)
1. English version of Japanese guidance for biologics in treating atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Oct; 50(10):e311-e322. PubMed ID: 37650357
[TBL] [Abstract][Full Text] [Related]
2. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
[TBL] [Abstract][Full Text] [Related]
3. Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations.
Butala S; Castelo-Soccio L; Seshadri R; Simpson EL; O'Shea JJ; Bieber T; Paller AS
J Allergy Clin Immunol Pract; 2023 May; 11(5):1361-1373. PubMed ID: 36948491
[TBL] [Abstract][Full Text] [Related]
4. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis.
Snast I; Reiter O; Hodak E; Friedland R; Mimouni D; Leshem YA
Am J Clin Dermatol; 2018 Apr; 19(2):145-165. PubMed ID: 29098604
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging biologics for the treatment of pediatric atopic dermatitis.
Ghamrawi R; Bell KA; Balogh EA; Strowd LC; Feldman SR
Expert Opin Biol Ther; 2020 Dec; 20(12):1435-1445. PubMed ID: 33078990
[TBL] [Abstract][Full Text] [Related]
6. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect.
Ratchataswan T; Banzon TM; Thyssen JP; Weidinger S; Guttman-Yassky E; Phipatanakul W
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1053-1065. PubMed ID: 33685604
[TBL] [Abstract][Full Text] [Related]
7. Biologics for Atopic Dermatitis.
Boguniewicz M
Immunol Allergy Clin North Am; 2020 Nov; 40(4):593-607. PubMed ID: 33012322
[TBL] [Abstract][Full Text] [Related]
8. Biological medication in atopic dermatitis.
Fölster-Holst R; Torrelo A; Das K; Murrell DF; Patil A; Rahmat Pour Rokni G; Grabbe S; Staubach P; Sohn A; Goldust M
Expert Opin Biol Ther; 2022 May; 22(5):643-649. PubMed ID: 34991429
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis.
Balakirski G; Burmann SN; Hofmann SC; Kreuter A
J Dermatolog Treat; 2023 Dec; 34(1):2258240. PubMed ID: 37705378
[No Abstract] [Full Text] [Related]
10. Biological Therapies for Atopic Dermatitis: A Systematic Review.
Zhou S; Qi F; Gong Y; Zhang J; Zhu B
Dermatology; 2021; 237(4):542-552. PubMed ID: 33735876
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of IL-13: A New Pathway for Atopic Dermatitis [Formula: see text].
Ratnarajah K; Le M; Muntyanu A; Mathieu S; Nigen S; Litvinov IV; Jack CS; Netchiporouk E
J Cutan Med Surg; 2021; 25(3):315-328. PubMed ID: 33350863
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of biologics in atopic dermatitis.
Wu J; Guttman-Yassky E
Expert Opin Biol Ther; 2020 May; 20(5):525-538. PubMed ID: 32003247
[No Abstract] [Full Text] [Related]
13. A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis.
Miyano T; Irvine AD; Tanaka RJ
Allergy; 2022 Feb; 77(2):582-594. PubMed ID: 33894014
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].
Kaneda N
Nihon Yakurigaku Zasshi; 2023; 158(3):282-289. PubMed ID: 37121713
[TBL] [Abstract][Full Text] [Related]
15. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
[TBL] [Abstract][Full Text] [Related]
16. Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases.
Kaufman BP; Alexis AF
Curr Allergy Asthma Rep; 2018 Aug; 18(10):55. PubMed ID: 30171358
[TBL] [Abstract][Full Text] [Related]
17. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.
Moyle M; Cevikbas F; Harden JL; Guttman-Yassky E
Exp Dermatol; 2019 Jul; 28(7):756-768. PubMed ID: 30825336
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in atopic dermatitis.
Li W; Man XY
Immunotherapy; 2022 Oct; 14(14):1149-1164. PubMed ID: 36046941
[TBL] [Abstract][Full Text] [Related]
20. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.
Kabashima K; Matsumura T; Komazaki H; Kawashima M;
Br J Dermatol; 2022 Apr; 186(4):642-651. PubMed ID: 34726262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
